Check Out our Selection & Order Now. Free UK Delivery on Eligible Orders To analyze the treatment and prognosis of T cell acute lymphoblastic leukemia(T-ALL)in adults. Method The clinicobiogical and survival data of 68 adult patients with newly diagnosis T-ALL were retrospectively analzyed. Results The median age of these 68 patients was 23 years(14-60 years).T-ALL was m . However, population-level data on its incidence and outcomes among adults is sparse. Using SEER database, we identified 1141 patients aged ≥20 years with pathologically confirmed T-ALL diagnosed between Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up D Hoezler and others Annals of Oncology, 2016. Vol 27, Supplement 5, Pages 69-82. Cancer and its management (7th edition) J Tobias and D Hochhauser. Wiley Blackwell, 2015. Cancer - principles and practice of oncology (10th. The survival rate of acute lymphoblastic leukemia (ALL) depends on the age of the patient and the response to chemotherapy. The average five-year survival in ALL is 68.1%. Survival rates continue to improve with newer and improved treatment modalities. The prognosis is better in those under 35 years of age, and children have the best prognosis
T-cell acute lymphoblastic leukemia (ALL) is a rare disease in adults with inferior survival outcomes compared with those seen in pediatric patients. Although potentially curable with ∼50% survival at 5 years, adult patients with relapsed disease have dismal outcomes with <10% of patients surviving long term . This result, although promising, is still less favorable than the outcome for all children People with acute lymphocytic leukemia (ALL) may have questions about their prognosis and survival. Prognosis and survival depend on many factors. Only a doctor familiar with a person's medical history, type of cancer, stage, characteristics of the cancer, treatments chosen and response to treatment can put all of this information together. The American Cancer Society's estimates for acute lymphocytic leukemia (ALL) in the United States for 2021 (including both children and adults) are: About 5,690 new cases of ALL (3,000 in males and 2,690 in females) About 1,580 deaths from ALL (900 in males and 680 in females) The risk for developing ALL is highest in children younger than 5. About 1,470 people will die from the disease in 2018. Several factors can determine survival rates, such as age at diagnosis and subtype of ALL. The five-year survival rate in the United States is..
Outcomes in adults with acute lymphoblastic leukemia are poor relative to what is observed in children, with less than half of people over 20 years of age expected to survive the illness. (PDUFA) of October 1, 2021. If approved, Tecartus would become the first and only CAR T-cell therapy approved for adults (≥18 years old) with. Oncology, ONCOLOGY Vol 9 No 5, Volume 9, Issue 5 Intensive remission chemotherapy followed by post-remission consolidation and maintenance therapies has achieved complete remission rates of 75% to 90% and 3-year survival rates of 25% to 50% in adults with acute lymphoblastic leukemia (ALL) What Is the Relative Survival Rate of Acute Myeloid Leukemia? The relative five-year survival rate for leukemia in general has more than quadrupled, from 14 percent in the 1960s to almost 66 percent from 2009 to 2015. However, the five-year survival rate for AML from 2009 to 2015 was lower — 29.4 percent overall The prevalence of t (9;22) in adult ALL can range from 15-50% and increases with age. 24 Ph-positivity has implications both in terms of prognosis and for treatment. Historically, Ph-positive ALL.. Adding the drug nelarabine (Arranon) to standard chemotherapy improves survival for children and young adults newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL), according to new results from an NCI-sponsored Children's Oncology Group (COG) clinical trial.. The trial was the largest ever conducted for patients with newly diagnosed T-ALL and T-cell lymphoblastic lymphoma (T-LL)
Leukemia survival rates are higher for people under the age of 55. Latest figures show that the 5-year survival rate for all subtypes of leukemia is 61.4 percent. Trusted Source. . A 5-year. Acute lymphoblastic leukemia (ALL) is a type of blood cancer. Learn more about the causes, risk factors, symptoms, diagnosis, treatment types, and prognosis for acute lymphoblastic leukemia
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 85 (8): 2025-37, 1995. [PUBMED Abstract] Linker CA, Levitt LJ, O'Donnell M, et al.: Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report Only 25 to 35 percent of adults live 5 years or longer. Acute myeloid leukemia (AML): With proper treatment, most people with this cancer can expect to go into remission. About 80 percent who go into remission will do so within 1 month of therapy. In some people, however, the disease will return, lowering the cure rate
Introduction. Patients with relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL) have a poor prognosis, with allogeneic hematopoietic stem cell transplantation (HSCT) generally viewed as the only curative option. 1-3 However, immuno-oncology therapy with blinatumomab, BiTE (a bispecific T-cell engager) molecule, has led to long-term survival among responders even in. Despite progress in the treatment of acute lymphoblastic leukemia (ALL), T-cell ALL (T-ALL) has limited treatment options, particularly in the setting of relapsed/refractory disease. Using an. Anand A. Patel, Joseph Thomas, Alexandra E. Rojek, Wendy Stock, Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults, Current Treatment Options in Oncology, 10.1007/s11864-020-00757-5, 21, 7, (2020) Adult T-cell leukemia/lymphoma (ATL or ATLL) is a rare cancer of the immune system's T-cells caused by human T cell leukemia/lymphotropic virus type 1 (). All ATL cells contain integrated HTLV-1 provirus further supporting that causal role of the virus in the cause of the neoplasm. A small amount of HTLV-1 individuals progress to develop ATL with a long latency period between infection and ATL. However, few of these patients are cured without a stem cell transplant. Standard-dose chemotherapy can induce a complete remission in 10%-30% of adults, but few patients are cured. The average duration of survival is 5-6 months and less than 5% of adult patients survive 5 years after relapse. Regimens Used for Reinduction Treatmen
1 This striking discrepancy between ALL incidence and leukemia-related mortality in the older adult highlights the detrimental impact of increasing age on ALL outcomes.. Treatment outcomes of ALL in older adults have been dismal, with a 5-year overall survival (OS) rate of approximately 20%. 2-7 Furthermore, in older patients with ALL, there is an inverse correlation between increasing age and. Abstract: Acute lymphoblastic leukemia (ALL) is an uncommon disease with poor outcomes in older patients. Although intensive chemotherapy can induce complete responses in older patients, the mortality rate is unacceptably high. The 5-year survival rate for patients achieving a remission ranges from 17% to 23%
While acute lymphoblastic leukemia in children is more common than other types of cancer, it has high cure rates. Survival rates are lower in adults, but they are improving. The 5-year relative survival rate for ALL is 68.8%. The statistics further break down to 90% in children and 30-40% in adults . Acute lymphocytic leukemia is the most common type of cancer in children, and treatments result in a good chance for a cure. Acute lymphocytic leukemia can also occur in adults, though the chance of a cure is greatly reduced Survival rates remain lower for babies (50%) and adults (35%). According to the National Cancer Intelligence Network (NCIN), generally for people with ALL: around 70 out of 100 people (70%) will survive their leukemia for 5 years or more after they are diagnosed
High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL) Leukemia , 20 ( 2006 ) , pp. 814 - 819 CrossRef View Record in Scopus Google Schola -- If Approved, Tecartus Would Be the First and Only CAR T-Cell Therapy Approved for Adult Patients (18 Years and Older) with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia- Weng, A. P. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306 , 269-271 (2004). ADS CAS Article PubMed PubMed Central Google Schola
What Is the Survival Rate of Acute Lymphoblastic Leukemia? The relative five-year survival rate from 2010 to 2016 was 68.8% according to Surveillance, Epidemiology, and End Results (SEER) data published by the National Cancer Institute T-cell acute lymphoblastic leukemia (T-ALL) accounts for about 15% and 25% of ALL in pediatric and adult cohorts respectively.1 Patients usually have high white blood cell counts and may present with organomegaly, particularly mediastinal enlargement and CNS involvement. The biological knowledge of TALL has until recently been rather limited The largest trial that has been completed to date in children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) has yielded the best survival data ever in this.
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood . 1995;85(8):2025-2037. 55 T-cell acute lymphoblastic leukemia/lymphoma is an aggressive hematological neoplasm whose classification is still based on immunophenotypic findings. Frontline treatment encompass high intensity combination chemotherapy with good overall survival; however, relapsing/refractory patients have very limited options. In the last years, the understanding of molecular physiopathology of this disease. Introduction. T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignant neoplasm of the bone marrow. It accounts for ∼20% of all cases of ALL and is somewhat more common in adults than children, although the incidence diminishes with older age. 1 Its clinical presentation can include hyperleukocytosis with extramedullary involvement of lymph nodes and other organs, including. T-cell acute lymphoblastic leukemia (T-ALL) is a variant of acute lymphoblastic leukemia, which is considered as the most common malignancy of childhood, comprising almost 10-15% of all cancers seen in the pediatric population . It is estimated that 15% of all ALLs in the pediatric population are T-ALL, whereas the ratio in adults rises up.
Today, nearly 90 percent of adults diagnosed with ALL achieve a complete remission, which means that leukemia cells can no longer be seen in the bone marrow with a microscope. Still, despite high remission rates, relapses still commonly occur in adults and survival rates for adult patients remain at approximately 20 to 40 percent Adult T-Cell Leukemia/Lymphoma. Adult T-cell leukemia/lymphoma (ATLL) is a rare and often aggressive (fast-growing) T-cell lymphoma that can be found in the blood (leukemia), lymph nodes (lymphoma), skin, or multiple areas of the body. ATLL has been linked to infection with the human T-cell lymphotropic virus type 1 (HTLV-1); however, less than.
Purpose of Review Genetically engineered T cells expressing a chimeric antigen receptor (CAR-T) targeting specific antigens present on acute lymphoblastic leukemia (ALL) blasts have generated promising results in children and adults with relapsed and refractory disease. We review the current evidence for CAR-T cell therapy in ALL, associated toxicities, and efforts to improve durable response. Acute lymphoblastic leukemia (ALL) is predominantly a childhood disease, with approximately 75% of cases occurring in patients younger than 6 years, but the incidence is bimodal, with the second peak occurring after age 60. 1 Over the past few decades, ALL has seen rapid treatment advances and improvement in outcomes. 3 This has been accomplished through both large collaborative group studies. The cadherin gene FAT1, located on chromosome 4q34-35 (ref. 1) within a region frequently deleted in human cancers, 2 encodes a large protein with 34 extracellular cadherin repea Acute lymphocytic leukemia (ALL) is the most common childhood cancer, but has a very high cure rate in children. It can appear in adults, too. It's a cancer of the blood and bone marrow Survival Rate and Prognosis. The 5-year survival rate for patients with acute lymphoblastic leukemia is at 70%. This is the median rate and there are variations between different age groups. The rate is highest in patients who are less than 14 years of age (90%) while lowest in those who are 65 years old and older (15%)
Chemotherapy combined with targeted therapies and improved supportive care has enhanced complete remission (CR) rate of newly diagnosed B cell acute lymphoblastic leukemia (B-ALL) to 85-90%, and long-term survival rate to 40-45% .However, about a third of standard-risk and two-thirds of high-risk patients experience recurrence [2, 3].. BackgroundThis study aimed to systematically evaluate and compare the efficacy and safety of consolidative hematopoietic stem cell transplantation (HSCT) after CD19 chimeric antigen receptor T (CAR-T) therapy with non-HSCT in the treatment of acute lymphoblastic leukemia (ALL).MethodsThe PubMed, Embase, Cochrane Library and Web of Science databases were searched for clinical trials Acute Lymphocytic Leukemia (ALL) - Symptoms, Causes, and Treatment. 4. Enlarged lymph nodes and organs. Enlarged lymph nodes and organs. As noted before, aberrant lymphocytes not only stay in the blood marrow and the blood. They migrate to other organs and deposit in lymph nodes, the spleen, and the liver The prognostic implications of DNMT3A genotype in T-cell acute lymphoblastic leukemia are incompletely understood. We performed comprehensive genetic and clinico-biological analyses of T-cell acute lymphoblastic leukemia patients with DNMT3A mutations treated during the GRAALL-2003 and -2005 studies. Eighteen of 198 cases (9.1%) had DNMT3A alterations
Introduction. Early T‐cell precursor acute lymphoblastic leukemia (ETP-ALL) is a subtype of T-cell acute lymphoblastic leukemia (T-ALL) recognized by the World Health Organization (WHO) in 2016, 1 accounting for 12.0-16.2% of childhood T-ALL 2 and 17.0-22.1% of adulthood T-ALL. 3 ETP cells originate from hematopoietic stem cells, a subset of cells that have just migrated from the bone. Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia, with an estimated 21,000 new cases diagnosed in 2018. The disease is virtually unheard of in children and it primarily affects older adults. Almost 90% of new cases are in people age 55 and older, while the average age at the time of diagnosis is 72
Overall, the 2-year leukemia-free survival and relapse incidence rates were 56.5% and 21%, respectively. The 100-day incidence of grade 2 through 4 acute graft-vs-host disease (GVHD) was 34.5%. The rates of nonrelapse mortality (NRM) and overall survival (OS) were 22.5% and 64.7%, respectively Therapy with Blincyto (blinatumomab), a CD19 BiTE (bispecific T-cell engager), demonstrated a longer survival time for patients with relapsed/refractory acute lymphoblastic leukemia, according to data published in Cancer.. Allogenic hematopoietic stem cell transplantation was typically viewed as the only curative option for patients with relapsed/refractory B-cell precursor acute lymphoblastic. Investigational CAR T-Cell Therapy in Acute Lymphoblastic Leukemia . February 25, 2021 is the furthest along in adult ALL [acute lymphoblastic leukemia]. Autolus Therapeutics is on their heels. Purpose: NOTCH signaling pathway is essential in T-cell development and NOTCH1 mutations are frequently present in T-cell acute lymphoblastic leukemia (T-ALL). To gain insight into its clinical significance, NOTCH1 mutation was investigated in 77 patients with T-ALL. Experimental Design: Detection of NOTCH1 mutation was done using reverse transcription-PCR amplification and direct sequencing. INTRODUCTION. Acute lymphoblastic leukemia/lymphoma (ALL/LBL) is the most common form of cancer in children, comprising approximately 30 percent of all childhood malignancies .Survival rates for ALL/LBL have improved dramatically since the 1980s, with current five-year overall survival rates >85 percent .Five-year event-free survival rates are >93 percent for low-risk groups 
Acute lymphocytic leukemia is most common in children, adolescents, and young adults, or those 15 to 39 years of age. ALL is most common in Hispanics and Whites. The rate of new cases of acute lymphocytic leukemia was 1.8 per 100,000 men and women per year based on 2014-2018 cases, age-adjusted The 5-year survival rate for people age 20 and older is 38%. The 5-year survival rate for people under age 20 is 89%. Recent advances in treatment have significantly lengthened the lives of people with ALL. However, survival rates depend on several factors, including biologic features of the disease and a person's age -- If Approved, Tecartus Would Be the First and Only CAR T-Cell Therapy Approved for Adult Patients (18 Years and Older) with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia. Despite an 85 to 90 percent cure rate after first treatment for children, adolescents and young adults with acute lymphoblastic leukemia (ALL), 10 to 15 percent of patients with pediatric ALL will experience relapse. ALL relapse can happen months or years following remission
A 'T-ALL' Order: Treating T-Cell Acute Lymphoblastic Leukemia. February 19, 2021. Erik Ness. CURE, Hematology Special Issue 2021, Volume 1, Issue 1. Oncologists and researchers are racing to identify new therapies to help better treat a rare form of acute lymphoblastic leukemia. Keith Owens had no time to be sick Treatment response rates in adults with lymphoblastic lymphoma range from 55-95%, with leukemia-type regimens producing rates higher than 70%. The 5-year disease-free survival rate is 45-55% in adults and 70-90% in children
T-cell acute lymphoblastic leukemia (T-ALL) is an uncommon aggressive leukemia arising from the malignant transformation of hematopoietic progenitors primed toward T-cell development. T-ALL accounts for approximately 10% to 15% of pediatric and 25% of adult ALL cases, and is characteristically more frequent in male than female Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival The clinical development TC-110 focus on the treatment of adult acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Preclinical data demonstrates that TC-110 is superior to CD19-CAR-T cells (carrying either 4-1BB or CD28 co-stimulatory domains) both in anti-tumor activity as well as the level.
Acute lymphoblastic lymphoma (ALL) is a very rare cancer that affects the blood cells and the immune system of the patient. Since it mainly occurs in people under the age of 35 and chiefly affects children-it is the most common cancer to affect children between the ages of 1 and 7-it is a disease that gets a lot of attention Shah B, Huynh V, Sender LS, et al. High rates of minimal residual disease-negative (MRD-) complete responses (CR) in adult and pediatric and patients with relapsed/refractory acute lymphoblastic. 201 Pfier nc. All ights eserved. une 201 • Estimated that by 2020, nearly 412,000 people worldwide will be diagnosed with some type of leukemia.2 • ALL accounts for approximately 12% of all leukemia cases worldwide.3 • For adult patients with relapsed or refractory ALL, the five-year overall survival rate is less than 10%.4,5 Acute Lymphoblastic
Acute lymphoblastic leukaemia develops in both children and adults, with a peak incidence between 1 year and 4 years. Most acute lymphoblastic leukaemia arises in healthy individuals, and predisposing factors such as inherited genetic susceptibility or environmental exposure have been identified in only a few patients. It is characterised by chromosomal abnormalities and genetic alterations. Acute lymphoblastic leukemia (ALL) is an aggressive type of leukemia of either B- or T-lineage immature lymphoid cells. ALL is primarily a childhood disease (ALL represents 75-80% of all acute leukemias in children ) and follows a bimodal distribution; the first peak occurs between 3 and 5 years of age and the second in adults older than 50 years Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia: Ma M, Wang X, Tang J, Xue H, Chen J, Pan C, Jiang H, Shen S: Front Med 2012 Dec;6(4):416-20: PMID 23065427 : FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitor
T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LL) are neoplasias of immature T-cell precursors con-sidered as a unique biological entity in the 2008 World Health Organization Classification of Hema-tologic Neoplasias1. Both entities are arbitrari-ly separated by a cut-off point of 20%-25% o ATLL has 4 subtypes. Depending on the different features, it is subclassified as smoldering, chronic, acute, or adult T-cell lymphoma. Lymphoma is a cancer of the lymph system. The acute and the adult T-cell lymphoma subtypes grow quickly. ATLL is caused by a retrovirus called the human T-cell leukemia virus (HTLV1). Sezary syndrome
In this study, we analyzed the prognostic relevance of genetic alterations, immunophenotypic markers, and microarray gene expression signatures in a panel of 53 adult T-ALL patients treated in the Eastern Cooperative Oncology Group E2993 clinical trial. An early immature gene expression signature, the absence of bi-allelic TCRG deletion, CD13 surface expression, heterozygous deletions of the. Outcomes in adults with acute lymphoblastic leukemia are poor relative to what is observed in children, with less than half of people over 20 years of age expected to survive the illness. It is on this background that CAR T-cell therapy with brexucabtagene autoleucel was tested in adults with relapsed B-ALL in ZUMA-3, said Bijal Shah, MD.
abst Ract T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malig-nancy characterized by aberrant proliferation of immature thymocytes. Despite an overall survival of 80% in the pediatric setting, 20% of patients with T-ALL ultimately die from relapsed or refractory disease SANTA MONICA, Calif. - Kite, a Gilead Company (Nasdaq: GILD), announced results from the primary analysis of ZUMA-3, a global, multicenter, single-arm, open-label Phase 1/2 study evaluating its chimeric antigen receptor (CAR) T-cell therapy Tecartus (brexucabtagene autoleucel) in adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
T-cell acute lymphoblastic leukemia (T-ALL) is a very aggressive type of blood cancer. The overall cure rate in children is about 80%, and about 45%-60% of adults have long-term disease-free. The median disease-free survival O'Brien et al noted that the complete remission rate was only 18% and the median survival et al. T-cell acute lymphoblastic leukemia in adults: clinical. Children and adolescents with relapsed acute lymphoblastic leukemia (ALL) are treated at Dana-Farber/Boston Children's Cancer and Blood Disorders Center through the Childhood Leukemia Program, one of the top pediatric leukemia treatment programs in the world.Our Program has played a leading role in refining treatment for childhood leukemia, resulting in today's cure rates of more than 90. Little information is available regarding late relapse in patients with T-lymphoblastic leukemia/lymphoma (T-LBL). Because of the aggressive nature of this disease, relapse is common and often happens early. Late relapses are rare and generally occur within a few years after initial remission. The relapse rate after 3 years has been reported to steadily decrease over time yet does not parallel. Despite all the available therapies, Acute Lymphoblastic Leukemia (ALL) remains extremely difficult to eradicate. Current available therapies, which include chemotherapy, radiation, and stem cell transplants, tend to be more successful in treating children than adults. While adults are more likely than children to relapse after treatment, the most common cause of treatment failure in children.
Acute lymphocytic leukemia is a type of acute leukemia. It's also called ALL and acute lymphoblastic leukemia. Acute means that it usually gets worse quickly if it's not treated. ALL is the most common type of cancer in children. It can also affect adults Childhood acute lymphoblastic leukemia is a genetically heterogeneous cancer that accounts for 10-15% of T-cell acute lymphoblastic leukemia (T-ALL) cases. The T-ALL event-free survival rate (EFS) is 85%. The evaluation of structural and numerical chromosomal changes is important for a comprehensive biological characterization of T-ALL, but there are currently no genetic prognostic markers
T-cell acute lymphoblastic leukemia (T-ALL) results from the collaboration of multiple genetic abnormalities in the transformation of T-cell progenitors. Plant homeodomain finger protein 6 (PHF6) has recently been established as a key tumor suppressor, which is mutated in T‑ALL; however, the clinical significance of PHF6 mutations has not been fully determined in adult T‑ALL Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children, representing one quarter of all pediatric cancers. The annual incidence of acute lymphoblastic leukemia within the United States is 3.7-4.9 cases per 100,000 children age 0-14 years, [ 4] with a peak incidence in children aged 2-5 years Objective: To review the clinical pharmacology, efficacy, and safety of blinatumomab for the treatment of pediatric and adult precursor B-cell acute lymphoblastic leukemia (B-ALL).Data Sources: A literature search of EMBASE (1947 to April 2015), Medline (1946 to April 2015), PubMed (1996 to April 2015), the U.S. National Institutes of Health Clinicaltrials.gov, the Food and Drug Administration. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Yasmin Abaza, Hagop M. Kantarjian, Stefan Faderl, Elias Jabbour, Nitin Jain, Deborah Thomas, Tapan Kadia, Gautam Borthakur, Joseph D. Khoury, Jan Burger, William Wierda, Susan O'Brien, Marina Konopleva,. Depending on your situation, the phases of treatment for acute lymphocytic leukemia can span two to three years. Treatments may include: Chemotherapy. Chemotherapy, which uses drugs to kill cancer cells, is typically used as an induction therapy for children and adults with acute lymphocytic leukemia